Melatonergic ligands. Pharmaceutical development and clinical applications

Current Pharmaceutical Design

Volumn 3, Issue 4, 1997, Pages 429-438

  Takaki, K S ^a  

^a BRISTOL MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 CHLOROMELATONIN; BENZOTHIOPHENE DERIVATIVE; LIGAND; LUZINDOLE; MELATONIN; MELATONIN DERIVATIVE; MELATONIN RECEPTOR; MELATONIN RECEPTOR AGONIST; MELATONIN RECEPTOR ANTAGONIST; NAPHTHALENE DERIVATIVE; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; CHICKEN; CIRCADIAN RHYTHM; DRUG ACTIVITY; DRUG DESIGN; DRUG DEVELOPMENT; DRUG RECEPTOR BINDING; HUMAN; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RABBIT; RAT; SHEEP; STRUCTURE ACTIVITY RELATION;

EID: 0030880294     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Lerner, A. B.; Case, J. D.; Takahashi, Y.; Lee, T. H.; Mori, W. J. Am. Chem. Soc. 1958, 80, 2587.
2. Yu, H.-S.; Reiter, R. J. Melatonin: Biosynthesis, Physiological Effects, and Clinical Applications: CRC Press: Boca Raton, 1993.
3. Arendt, J. Melatonin and the Mammalian Pineal Gland; Chapman and Hall: London, 1995.
4. Reiter, R. Mol. Cell. Endocrinol. 1991, 79, C153-C158.
5. Mistlberger, R. E.; Bergmann, B. M.; Waldenar, W.; Rechtschaffen, A. Sleep 1983, 6, 217-233.
6. Refinetti, R.; Kaufman, C. M.; Menaker, M. J. Camp. Physiol [A] 1994, 175, 223-232.
7. Satlin, A.; Stopa, E. G. Society for Neurosciences Abstracts 1993, 19, 568.
8. Ebisawa, T.; Karne, S.; Lerner, M. R.; Reppert, S. M. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 6133-6137.
9. Reppert, S. M.; Weaver, D. R.; Ebisawa, T. Neuron 1994, 13, 1177-1185.
10. Reppert, S. M.: Godson, C.; Mahle, C. D.; Weaver, D. R.; Slaugenhaupt, S. A.; Gusella, J. F. Proc. Natl Acad. Sci., U.S.A. 1995, 92, 8734-8738.
11. Reppert, S. M.; Weaver, D. R.; Cassone, V. M.; Godson, C.; Kolakowski, L. Neuron 1995, 15, 1003-1015.